Nathalie Arendt
PhD student at Department of Medical Cell Biology; Research group Femke Heindryckx
- E-mail:
- nathalie.arendt@mcb.uu.se
- Visiting address:
- BMC
Husargatan 3
751 23 Uppsala - Postal address:
- Box 571
751 23 UPPSALA
Publications
Recent publications
-
Part of FEBS Open Bio, 2026
- DOI for Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling
- Download full text (pdf) of Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling
-
Part of Therapeutic Advances in Medical Oncology, 2026
- DOI for Prevalence of gastrointestinal side effects in hepatocellular carcinoma patients receiving sorafenib: a meta-analysis of 136 studies and 14,416 patients
- Download full text (pdf) of Prevalence of gastrointestinal side effects in hepatocellular carcinoma patients receiving sorafenib: a meta-analysis of 136 studies and 14,416 patients
-
Part of Biomedicine and Pharmacotherapy, 2025
- DOI for A comparative study of idarubicin and doxorubicin in a chemically-induced in vivo mouse model for hepatocellular carcinoma
- Download full text (pdf) of A comparative study of idarubicin and doxorubicin in a chemically-induced in vivo mouse model for hepatocellular carcinoma
-
Part of Therapeutic Advances in Medical Oncology, p. 1-30, 2025
- DOI for Gastrointestinal side effects in hepatocellular carcinoma patients receiving transarterial chemoembolization: a meta-analysis of 81 studies and 9495 patients
- Download full text (pdf) of Gastrointestinal side effects in hepatocellular carcinoma patients receiving transarterial chemoembolization: a meta-analysis of 81 studies and 9495 patients
-
Part of European Journal of Pharmacology, 2025
- DOI for Statin-mediated protection in chemotherapy-induced intestinal and cardiac toxicity: current perspectives
- Download full text (pdf) of Statin-mediated protection in chemotherapy-induced intestinal and cardiac toxicity: current perspectives
All publications
Articles in journal
-
Part of FEBS Open Bio, 2026
- DOI for Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling
- Download full text (pdf) of Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling
-
Part of Therapeutic Advances in Medical Oncology, 2026
- DOI for Prevalence of gastrointestinal side effects in hepatocellular carcinoma patients receiving sorafenib: a meta-analysis of 136 studies and 14,416 patients
- Download full text (pdf) of Prevalence of gastrointestinal side effects in hepatocellular carcinoma patients receiving sorafenib: a meta-analysis of 136 studies and 14,416 patients
-
Part of Biomedicine and Pharmacotherapy, 2025
- DOI for A comparative study of idarubicin and doxorubicin in a chemically-induced in vivo mouse model for hepatocellular carcinoma
- Download full text (pdf) of A comparative study of idarubicin and doxorubicin in a chemically-induced in vivo mouse model for hepatocellular carcinoma
-
Part of Therapeutic Advances in Medical Oncology, p. 1-30, 2025
- DOI for Gastrointestinal side effects in hepatocellular carcinoma patients receiving transarterial chemoembolization: a meta-analysis of 81 studies and 9495 patients
- Download full text (pdf) of Gastrointestinal side effects in hepatocellular carcinoma patients receiving transarterial chemoembolization: a meta-analysis of 81 studies and 9495 patients
-
Part of European Journal of Pharmacology, 2025
- DOI for Statin-mediated protection in chemotherapy-induced intestinal and cardiac toxicity: current perspectives
- Download full text (pdf) of Statin-mediated protection in chemotherapy-induced intestinal and cardiac toxicity: current perspectives
-
Part of European journal of pharmaceutics and biopharmaceutics, 2025
- DOI for A comprehensive mechanistic investigation of factors affecting intestinal absorption and bioavailability of two PROTACs in rats
- Download full text (pdf) of A comprehensive mechanistic investigation of factors affecting intestinal absorption and bioavailability of two PROTACs in rats